Promoting self-compassion meditation with intranasal oxytocin in borderline personality disorder: a pilot study.

Psychiatry ResJun 17, 2026 (epub)
Clinical ResearchPsychiatry

Maria Arqueros, Joaquim Soler, David Almenta et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial investigated the effects of intranasal oxytocin (24 IU) on compassion meditation quality in 18 individuals with borderline personality disorder (BPD). The study found that oxytocin significantly improved scores on the imagination dimension of compassion practice quality compared to placebo, suggesting a potential role in enhancing therapeutic engagement.

Key findings

  • Oxytocin was associated with higher endpoint scores on the imagination dimension of compassion practice quality compared to placebo.
  • No significant differences were found for the total score or somatic dimension of compassion practice.
  • No adverse effects related to oxytocin administration were reported.

Why it matters

Understanding the role of oxytocin in enhancing compassion-based practices could improve therapeutic outcomes for individuals with BPD, who often struggle with self-criticism and emotional dysregulation.

Source

PubMed · PMID 42372695

Published in Psychiatry Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.